Richard Kim, MD, Professor, clinical and research interests focus on gastrointestinal tumors, in particular, hepatobiliary and colon cancer at Moffitt Cancer Center. He is a principal investigator in multiple investigator-initiated and pharmaceutical phase I and II trials using novel targeted agents. In this video, he speaks to us about the ASCO 2022 Abstract – Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI for metastatic colorectal cancer (CRC) in KEYNOTE-651: Long-term follow-up of cohorts B and D.
Overview:
The goal of this study is to determine the safety and tolerability of the following combinations, as well as to establish a preliminary recommended Phase 2 dose (RP2D): pembrolizumab plus binimetinib (Cohort A), pembrolizumab plus mFOLFOX7 (oxaliplatin 85 mg/m2; leucovorin [calcium folinate] 400 mg/m2; fluorouracil [5-FU] 2400 mg (Cohort E).